Morocco’s King His Majesty Mohammed VI recently chaired the launch and signing ceremony of the country’s Covid-19 vaccine manufacturing plant to boost Africa’s vaccine sovereignty with first trial batches scheduled for July 30.
The launch is King Mohammed VI’s vision to position his country as a key biotechnology hub in Africa and in the world, capable of meeting the health needs of the continent in the short and long term.
King Mohammed VI’s thriving vision also seeks to integrate pharmaceutical research, clinical development, manufacturing and marketing of biopharmaceutical products by mobilising investments between 400 to 500 million euros.
Through the project, Morocco is set to manufacture vaccines (Covid-19 and other vaccines), with three industrial lines that have a combined production capacity targeting 116 million units in 2024.
Between 2022-2025, the large-scale investment project aims to transfer the aseptic filling and active substance manufacturing of more than 20 vaccines and bio-therapeutic products, including three Covid-19 vaccines.
Morocco is set to achieve this feat in less than three years, covering more than 70 percent of its citizen’s needs and more than 60 percent of those being for Africa.
Recipharm, a Swedish company ranking among world leaders in biotechnology and the “fill & finish” industry, will ensure Morocco’s vaccine self-sufficiency and make the country a leading biotechnology platform on the African continent and the world.
Vaccine production capacity is projected to increase to about five million doses starting in February 2022 and to more than 20 million doses per month by the end of 2022. By 2025, Morocco will be able to produce more than two billion doses of vaccine.